TABLE 2.
Size, position, GC percentage, and content of the large variably present gene cluster identified in this study
| Cluster IDa | Size (no. of ORFs) | Start site | End site | G+C content (%) | Gene product(s) or function | Other characteristicsb | GI IDa,c |
|---|---|---|---|---|---|---|---|
| VPC-01 | 52 | VP0187 | VP0238 | 40.6 | O3:K6 antigen biosynthesis | ||
| VPC-02 | 28 | VP0376 | VP0403 | 40.9 | Type I restriction modification system | T, P | VPaI-1 |
| VPC-03 | 22 | VP1071 | VP1092 | 42.1 | Phage family integrase, putative ATP-dependent DNA helicase | T, P | VPaI-3 |
| VPC-04 | 38 | VP1383 | VP1420 | 43.3 | Hypothetical protein, conserved hypothetical protein | ||
| VPC-05 | 39 | VP1548 | VP1586 | 47.5 | Bacteriophage f237, Alteromonas phage PM2 | P | |
| VPC-06 | 94 | VP1771 | VP1864 | 41.8 | Superintegron (hypothetical protein, conserved hypothetical protein) | P | |
| VPC-07 | 14 | VP2131 | VP2144 | 38.9 | Hypothetical protein, putative phage-related protein | T, P | VPaI-4 |
| VPC-08 | 11 | VP2900 | VP2910 | 38.3 | Hypothetical protein, putative phage protein | P | VPaI-5 |
| VPC-09 | 15 | VPA0434 | VPA0448 | 44.2 | Hypothetical protein, putative RNase HI, resolvase, recombinase | P | |
| VPC-10 | 25 | VPA0889 | VPA0913 | 48.2 | Hypothetical protein, phage-related protein, Alteromonas phage PM2 | P | |
| VPC-11 | 17 | VPA1254 | VPA1270 | 43.4 | Putative IS1328 transposase, hypothetical protein | P | VPaI-6 |
| VPC-12 | 87 | VPA1310 | VPA1396 | 39.2 | Vp-PAI (pathogenicity island) | K | VPaI-7 |
| VPC-13 | 10 | VPA1700 | VPA1709 | 49.1 | Mannose metabolism |
a
ID, identifier.
b
T, flanked by tRNA gene; P, contains pandemic strain-specific genes; K, KP-positive clinical strain specific.
c
GI ID assigned by Hurley et al. (10).